We adopted the in silico approach of structure-based virtual screening and ensemble docking to repurpose approved drugs for the treatment of cancers that involve CDK2 regulation, with a major focus on human hepatocellular carcinoma (HCC). The gene discussed is CDK2; the disease is hepatocellular carcinoma.